The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Review Article
Managing Asthma: An Evidence-Based Approach to Optimizing Inhaled Corticosteroid Treatment
Abstract
Asthma is a chronic disease characterized by airway inflammation and hyperresponsiveness and is associated with significant yet avoidable mortality and morbidity resulting in considerable individual and societal burden. Inhaled corticosteroids are the most effective class of controller medication available today for treating persistent asthma and are the evidence-based guideline-recommended first-line treatment for controlling asthma. Although inhaled corticosteroids have proven to reduce asthma-related exacerbations that lead to hospitalizations and death, recent studies have shown that only a small percentage of patients receive appropriate treatment and monitoring for their asthma. Delivering optimal asthma management requires an understanding and application of basic science and evidence-based guidelines in clinical practice. Management of a chronic disease in the primary care setting requires overcoming several barriers due to competing priorities and time constraints of the physician, as well as the reluctance of patients to actively participate in their own care. However, evidence has shown that the patient-centered medical home model can overcome some of these issues and improve patient outcomes and adherence to therapy.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. GINA—the global initiative for asthma. 2008. Available at: http://ginasthma.org. Accessed May 13, 2009.
2. National Center for Health Statistics. Asthma prevalence, health care use and mortality: United States, 2003–2005. Available at: http://www.dcd.gov/nchs/products/pubs/pubd/hestats/asthma03-05/asthma03-05.htm 2009.
3. Horak E, Sawyer SM, Roberts M, et al. Impact of disease severity on quality of life in adults with asthma. Wien Klin Wochenschr 2005;117:462–467.
4. Carlton BG, Lucas DO, Ellis EF, et al. The status of asthma control and asthma prescribing practices in the United States: results of a large prospective asthma control survey of primary care practices. J Asthma 2005;42:529–535.
5. Asthma and Allergy Foundation of America. Cost of asthma. 2006. Available at: http://www.aafa.org/display.cfm?id=6⊂=63.
6. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact [review]. J Allergy Clin Immunol 2001;107:3–8.
7. QuickStats: health-care visits for asthma, by medical setting and health-insurance status—United States, 2003 [serial online]. MMWR Morb Mortal Wkly Rep 2006;55:405.
8. National Heart Lung and Blood Institute, National Asthma Education and Prevention Program.Managing Exacerbations of Asthma: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma [serial online]. Bethesda, National Asthma Education and Prevention Program, National Heart Lung and Blood Institute, 2007, 373–417.
9. Braman SS. The global burden of asthma. Chest 2006;130:4S–12S.
10. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107–1136.
11Adams RJ, Wilson DH, Taylor AW, et al. Coexistent chronic conditions and asthma quality of life: a population-based study. Chest 2006;129:285–291.
12. Magnan A, Meunier JP, Saugnac C, et al. Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study. Allergy 2008;63:292–298.
13. Valovirta E, Pawankar R. Survey on the impact of comorbid allergic rhinitis in patients with asthma. BMC Pulm Med 2006;6(suppl 1):S3.
14. Crystal-Peters J, Neslusan C, Crown WH, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109:57–62.
15. Harding SM. Gastroesophageal reflux and asthma: insight into the association. J Allergy Clin Immunol 1999;104:251–259.
16. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120:S94–S138.
17. Wilson NM. Wheezy bronchitis revisited. Arch Dis Child 1989;64:1194–1199.
18. Chiang WC, Goh A, Ho L, et al. Paradoxical vocal cord dysfunction: when a wheeze is not asthma. Singapore Med J 2008;49:e110–e112.
19. Sly PD, Cahill P, Willet K, et al. Accuracy of mini peak flow meters in indicating changes in lung function in children with asthma. BMJ 1994;308:572–574.
20. Frey U, Stocks J, Coates A, et al. Specifications for equipment used for infant pulmonary function testing. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/American Thoracic Society. Eur Respir J 2000;16:731–740.
21. Birnbaum S, Barreiro TJ. Methacholine challenge testing: identifying its diagnostic role, testing, coding, and reimbursement. Chest 2007;131:1932–1935.
22. Thomas M, Price D. Impact of comorbidities on asthma. Expert Rev Clin Immunol 2008;4:731–742.
23. Spahn JD, Covar RA. Weighing the risks of treatment versus nontreatment in pediatric asthma. Pediatr Clin North Am 2003;50:677–695.
24. Skoner JD, Schaffner TJ, Schad CA, et al. Addressing steroid phobia: improving the risk-benefit ratio with new agents. Allergy Asthma Proc 2008;29:358–364.
25. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments [review]. Am J Respir Crit Care Med 1998;157:S1–S53.
26. Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292:367–376.
27. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality [review]. J Allergy Clin Immunol 2001;107:937–944.
28. Nelson HS, Weiss ST, Bleecker ER, et al; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15–26.
29. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma [review]. Allergy 2006;61:518–526.
30. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003;112:469–478; quiz 479.
31. Derendorf H. Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy. Allergy Asthma Proc 2005;26:327–335.
32. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004;126:213–219.
33. Canonica GW, Baena-Cagnani CE, Blaiss MS, et al; GAPP Survey Working Group. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) survey: global adult findings. Allergy 2007;62:668–674.
34. Juniper EF. The impact of patient compliance on effective asthma management [review]. Curr Opin Pulm Med 2003;9(suppl 1):S8–S10.
35. Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 2004;4:191–195.
36. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50:1313–1321; discussion 1321–1322.
37. Feddah MR, Brown KF, Gipps EM, et al. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci 2000;3:318–324.
38. Sutherland ER, Martin RJ. Targeting the distal lung in asthma: do inhaled corticosteroids treat all areas of inflammation? Treat Respir Med 2005;4:223–229.
39. Dolovich MA. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care 2000;45:597–608.
40. Dietzel K, Engelstätter R, Keller A. Ciclesonide: An On-Site-Activated Steroid, in Hansel TT, Barnes PJ (eds): New Drugs for Asthma, Allergy and COPD Progress in Respiratory Research. Switzerland, Karger, 2001, vol 31, pp 91–93.
41. Cerasoli F Jr. Developing the ideal inhaled corticosteroid [review]. Chest 2006;130:54S–64S.
42. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005;12:201–209.
43. Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Aff (Millwood) 2001;20:64–78.
44. Kellerman R. The patient centered medical home—a new model of practice in the USA. Aust Fam Physician 2009;38:279.
45. Stewart M, Marshall JN, Østbye T, et al. Effectiveness of case-based on-line learning of evidence-based practice guidelines. Fam Med 2005;37:131–138.
46. Wang YY. Patient-centered medicine: transforming the clinical method. Second edition. Int J Integr Care 2005;5:1–2.
47. Krigsman K, Nilsson JL, Ring L. Adherence to multiple drug therapies: refill adherence to concomitant use of diabetes and asthma/COPD medication. Pharmacoepidemiol Drug Saf 2007;16:1120–1128.
48. Gibson PG, Ram FS, Powell H. Asthma education. Respir Med 2003;97:1036–1044.
49. Cowie RL, Revitt SG, Underwood MF, et al. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest 1997;112:1534–1538.
50. Irwin RS, Richardson ND. Patient-focused care: using the right tools [review]. Chest2006;130:73S–82S.
51. Broder MS, Chang EY, Ory C, et al. Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care population. Allergy Asthma Proc 2009;30:148–157.
